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ABSTRACT
We studied a family with severe primary osteoporosis carrying a heterozygous p.Arg8Phefs*14 deletion in COL1A2, leading to hap-
loinsufficiency. Three affected individuals carried themutation and presented nearly identical spinal fractures but lacked other typical
features of either osteogenesis imperfecta or Ehlers-Danlos syndrome. Although mutations leading to haploinsufficiency in COL1A2
are rare, mutations in COL1A1 that lead to less protein typically result in a milder phenotype. We hypothesized that other genetic
factors may contribute to the severe phenotype in this family. We performed whole-exome sequencing in five family members
and identified in all three affected individuals a rare nonsense variant (c.1282C > T/p.Arg428*, rs150257846) in ZNF528. We studied
the effect of the variant using qPCR and Western blot and its subcellular localization with immunofluorescence. Our results indicate
production of a truncated ZNF528 protein that locates in the cell nucleus as per the wild-type protein. ChIP and RNA sequencing ana-
lyses on ZNF528 and ZNF528-c.1282C > T indicated that ZNF528 binding sites are linked to pathways and genes regulating bone
morphology. Compared with the wild type, ZNF528-c.1282C > T showed a global shift in genomic binding profile and pathway
enrichment, possibly contributing to the pathophysiology of primary osteoporosis. We identified five putative target genes for
ZNF528 and showed that the expression of these genes is altered in patient cells. In conclusion, the variant leads to expression of
truncated ZNF528 and a global change of its genomic occupancy, which in turn may lead to altered expression of target genes.
ZNF528 is a novel candidate gene for bone disorders andmay function as a transcriptional regulator in pathways affecting bonemor-
phology and contribute to the phenotype of primary osteoporosis in this family together with the COL1A2 deletion. © 2020 The
Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral
Research (ASBMR).
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Osteogenesis imperfecta (OI) is a rare genetic disorder char-acterized by low bone mass and bone fragility.(1) Classical
OI types are inherited in an autosomal dominant manner, but
autosomal recessive forms have also been reported.(1–4) Clinical
manifestations of OI range from mild symptoms to severe bone
deformities and neonatal lethality.(5) Most OI cases are caused
by mutations in the genes encoding for collagen I alpha chains,
COL1A1 and COL1A2.(6) Other OI-causing mutations are often in
genes involved in the synthesis, posttranslational modification,
trafficking, or secretion of collagen I.(7–12) In addition, mutations
in the zinc-finger transcription factor Sp7 (a.k.a. Osterix) required
for osteoblast differentiation and bone formation have been
reported to cause an autosomal recessive form of OI.(13–15)
Collagen I is a triple helical protein formed of two alpha 1 and
one alpha 2 chains. The triple helical structure is formed from a
repeating region where every third amino acid is a glycine.(16)
Mutations affecting this region disturb the interaction with other
collagen chains and lead to synthesis of abnormally structured
collagen I.(16) This is a common mutation type in OI types II to IV,
where clinical phenotype ranges frommoderate to lethal.(6) Muta-
tions affecting the N-propeptide cleavage site cause another con-
nective tissue disorder called Ehlers-Danlos syndrome (EDS).(17)
EDS is a group of disorders characterized by fragility of connective
tissue, atrophic scarring, skin hyperextensibility, hypermobility of
joints, and abnormal bruising. The EDS type caused by mutations
in the collagen I encoding genes is a rare autosomal dominant
arthrochalasic form characterized by serious joint hypermobility,
hip dysplasia, skin hyperextensibility, bruising, arthropic scars,
kyphoscoliosis, and osteopenia.(18)
The mildest OI, type I, is often caused by heterozygous muta-
tions in COL1A1, leading to nonsense mediated decay and hap-
loinsufficiency.(6) Homozygous or compound heterozygous
mutations causing complete lack of collagen I alpha 2 chain typ-
ically result in EDS with a defect in cardiac valve,(19–21) but in
some cases they have been associated with moderate or severe
OI.(22–25) In addition, a mixed EDS/OI phenotype has been
described.(26) There is no clear understanding of themechanisms
leading to differential outcomes of the lack of collagen I alpha2
chain. It has been suggested that in some OI cases the observed
mutations may not lead to complete lack of COL1A2 and some
misfolded protein might accumulate in the cell.(22) Mutations
leading to haploinsufficiency are very rare in COL1A2.(27,28) In
COL1A1 and in COL2A1, coding for collagen II, mutations leading
to reduced protein, rather than defected protein, typically result
in milder phenotypes.(6,29)
Although there is some correlation between collagen I mutation
types and different phenotypes, this relationship is complex and
identicalmutations in the collagen I genesmay result in phenotypic
variability in OI even within families with identical mutations.(30,31)
Other genetic factors are likely to contribute to this variability. How-
ever, no such modifiers have previously been identified.
Heterozygous p.Arg8Phefs*14 deletion in COL1A2 leading to
nonsense mediated decay was recently identified in a Finnish
family with primary osteoporosis.(32) Three affected individuals
carried the mutation and presented nearly identical spinal frac-
tures in radiographs, but they lacked otherwise typical features
for both OI and EDS, such as blue sclerae, dentinogenesis imper-
fecta, hypermobility, muscle weakness, deformities, and short
stature. In this family, all affected individuals had severe early
onset primary osteoporosis with low bone mineral density
(BMD) and several spinal fractures since childhood. We
hypothesized that other genetic factors may contribute to the
severe phenotype and thus performed whole-exome sequenc-
ing in five members of the family. We identified a pathogenic
variant in ZNF528 transcription factor likely to affect the pheno-
type by altering the expression of its target genes in pathways
affecting bone morphology.
Materials and Methods
Methods are described in more detail in the Supplemental Mate-
rials and Methods.
Patients
Affected individuals in the family, the father and two sons, had
suffered from multiple compression fractures of the vertebrae.
The pedigree of the family is presented in Supplemental
Fig. S1. By the age of 30 years, the father had already been diag-
nosed with multiple compression fractures and he had lost 5 cm
of adult height. The sons had been diagnosed with compression
fractures in childhood, at the age of 8 and 12 years
(Supplemental Fig. S2). They also had persistently low lumbar
spine BMD but normal BMD at the proximal hip (Supplemental
Fig. S2; Supplemental Table S1). The mother, third son, and three
siblings of the father were unaffected. The family has previously
been described in more detail.(32)
DNA samples were available from all eight family members
(three affected, five unaffected). Genomic DNA was extracted
from EDTA blood samples using standard procedures. DNA sam-
ple quality and quantity were characterized by NanoDrop mea-
surement. Primary skin fibroblasts were available from two
affected family members (I2 and II2, Supplemental Fig. S1) and
three unrelated controls. This study was approved by the Ethics
Committee of the Hospital District of Helsinki and Uusimaa,
and family members gave their informed written consent.
Whole-exome data analysis
DNA samples from five family members (Supplemental Fig. S1)
were studied using whole-exome sequencing. DNA was frag-
mented and enriched at the BGI (http://www.genomics.cn/en/
index) by using NimbleGen SeqCap EZ Human Exome v3.0 kit.
The enriched DNA was subjected to Illumina (San Diego, CA,
USA) HiSeq sequencing. Clean reads were then aligned with
the reference genome (hg19) and quality controlled according
to the BGI Bioinformatics (Cambridge, MA, USA) pipeline.
Private or rare (minor allele frequency [MAF] < 0.01) variants
that were shared by the affected individuals and were not pre-
sent in the unaffected individuals were studied further. These
variants were functionally annotated using wANNOVAR to iden-
tify variants estimated to be pathogenic by SIFT, Polyphen-2, and
Mutation Taster. Variants were validated using capillary
sequencing with ABI3500xL Genetic Analyzer (Applied
Biosystems, Carlsbad, CA, USA) from all family members to find
alleles co-segregating with the phenotype.
Expression of the ZNF528 in vitro
ZNF528 pcDNA3.1 constructs
To study the effect of the ZNF528 c. 1282C > T/p.Arg428* variant,
two expression constructs were made: a wild-type ZFF528
(V5-ZNF528-WT) and a construct with the identified variant
(V5-ZNF528-c.1282C > T). Before qPCR and Western blot
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experiments, cells were transiently transfected with
V5-ZNF528-WT or V5-ZNF528-c.1282C>T constructs.
Real-time quantitative polymerase chain reaction (qPCR)
Real-time qPCR was carried out in duplicate using iTaq SYBR
Green Supermix kit (Bio-Rad, Hercules, CA, USA) in accordance
with the manufacturer’s instructions in a CFX96 Real-Time Sys-
tem instrument (Bio-Rad). Data were analyzed using the 2
(−Delta Delta C(T)) –method.(33) Beta-actin (ACTB) and beta-
2-microtubulin (B2M) were used as reference genes for HEK293
cells and hypoxanthine-guanine phosphoribosyltransferase
1 (HPRT1) and succinate dehydrogenase complex flavoprotein
subunit A (SDHA) for primary skin fibroblasts.
Western blot
Proteins were separated by 10% SDS-PAGE and transferred onto
0.45-μm PVDF membrane (Immobilon-P, Millipore, Bedford, MA,
USA). The membrane was exposed to antibodies (1:1000 dilu-
tion) V5-HRP (Invitrogen, Carlsbad, CA, USA) or β-actin-HRP
(Abcam, Cambridge, UK), and signal was imaged using a
LAS-3000 Luminescent Image Analyzer (FujiFilm, Tokyo, Japan).
The protein bands were normalized to β-actin and Image J soft-
ware (National Institute of Mental Health, Bethesda, MD, USA)
was used to quantify immunoblots.
Protein expression and subcellular localization of ZNF528
Lentiviral constructs, lentivirus production, and infection of Saos-2
cell line
Saos-2 cell lines stably expressing V5-ZNF528-WT and
V5-ZNF528-c.1282C > T were created using lentivirus infection
as described in the Supplemental Material and Methods. The
V5-ZNF528-WT and V5-ZNF528-c.1282 C > T expressing lentivi-
ruses were produced in HEK293T cells using the second-
generation lentivirus packaging system. The Saos-2 cell lines
were sorted by FACS using BD FACSAria flow cytometer
(BD Biosciences, Heidelberg, Germany).
Immunofluorescence
Saos-2 cells overexpressing V5-ZNF528-WT, V5-ZNF528-
c.1282C > T, or empty vector were fixed in 4% paraformaldehyde
and permeabilized with 0.1% Triton X-100. The cells were
incubated with primary V5 antibody (Invitrogen, Carlsbad, CA,
USA) and fluorescent-conjugated secondary antibody Alexa488
(Invitrogen). To stain nucleus, the cells were incubated
with 2-(4-amidinophenyl)-1H-indole-6-carboxamidine (DAPI)
(Sigma-Aldrich, St. Louis, MO, USA) and with TRITC-Phalloidin
(Sigma-Aldrich) to stain actin filaments. A Zeiss LSM 780 confocal
microscope was used for confocal laser scanning images analysis,
using a × 40 Plan-Apochromat objective, and analyzed by the
ZEN 2011 software (Zeiss, Thornwood, NY, USA).
Cell viability and cytotoxicity assays
To assess whether V5-ZNF528-WT or V5-ZNF528-c.1282C > T
induce cell death, cell viability and cytotoxicity assays were per-
formed. Experiments were performed in triplicate and statistical
significance was calculated by two-tailed Student’s t test with
equal variances.
ZNF528 in databases
Expression Atlas (www.ebi.ac.uk/gxa), the Genotype-Tissue
Expression (GTEx) v5 (www.gtexportal.org), and Cell Line Naviga-
tor (www.medicalgenomics.org/celllinenavigator) databases
were used to study the expression of ZNF528 in tissues and cell
lines.
Chromatin immunoprecipitation (ChIP) sequencing
Chromatin DNA was purified by MinElute PCR Purification Kit
(Qiagen, Chatsworth, CA, USA). The ChIP sequencing library
was built by using the TruSeq ChIP Sample Preparation kit
(Illumina). The library was sequenced using a NextSeq550
sequencing system (Illumina).
ChIP sequencing data analysis
The peak regions across the genome (hg19) were annotated and
peak-associated genes and differentially expressed genes from
RNA sequencing for V5-ZNF528-WT, V5-ZNF528-c.1282C > T
were intersected. Functional enrichment analysis was performed
using HOMER and Genomic Regions Enrichment of Annotations
Tool (GREAT). The analysis of distribution of ChIP sequencing
peaks across the genome was performed using R package
ChIPseeker.
In addition, re-analysis was performed for the ChIP sequenc-
ing data of wild-type ZNF528 that is publicly available (http://
zifrc. ccbr.utoronto.ca/) and reported earlier.(34) To investigate
whether the ChIP sequencing peaks are linked to genes with
any functional annotations, ontology analysis was performed
using GREAT. An enrichment analysis was carried out for gene
ontology biological process (GO BP) terms and mouse and
human phenotypes. Among these pathways, genes that had
the ZNF528 binding site and had a previously known connection
to bone phenotypes were identified. These genes were consid-
ered as potential ZNF528 target genes for further analyses.
RNA sequencing
RNA was prepared from Saos-2 cells overexpressing either
V5-ZNF528-WT or V5-ZNF528-c.1282C > T and control cells
expressing empty vector each with two replicates. Illumina Tru-
Seq Stranded mRNA Library preparation kit was used according
to themanufacturer’s instructions. Illumina NextSeq550 platform
was used to sequence the RNA libraries, with single-ended and
76 cycle mode. The FASTQ data were prepared within BaseSpace
(Illumina). Correlation of expression between replicates is pre-
sented in Supplemental Fig. S3.
Differential gene expression analyses
RNA sequencing
RNA sequencing data analysis was performed as previously
described(35) with minor modifications. DESeq2 version 1.22.2
was applied to perform differential gene expression analysis in
R (version 3.5.2). For calling differentially expressed genes, the
false discovery rate (FDR) cut-off was set to <0.01. The read
counts were normalized with shifted logarithm transformation
for plotting heat maps using R package pheatmap (version
1.0.12). Functional enrichment analysis usingWikiPathways data-
base was performed via HOMER. OsteoporosAtlas database was
used to identify osteoporosis-related genes, and statistical
enrichment was evaluated using Pearson’s chi-square test.
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Differentally expressed genes in patient fibroblasts
Genes identified as potential target genes in the ChIP sequenc-
ing data sets were studied in the in vitro RNA sequencing data
and in the patients’ primary skin fibroblasts using qPCR. Primers
used in qPCR are presented in Supplemental Table S2.
Results
Whole-exome data analysis
In the three affected family members, we observed altogether
239 exonic variants that were not detected in the other two unaf-
fected individuals or in an in-house exome data set (n = 71).
Functional annotation identified nine rare variants with six indi-
cating deleterious (harmful) effects through in silico prediction
and three lacking such prediction. These nine variants were gen-
otyped in all eight family members. Two single nucleotide vari-
ants (SNVs) co-segregated with the disease: a nonsense
mutation (rs150257846) in the zinc finger protein 528 gene
(ZNF528) and a missense SNV (rs192842795) in the synapse
defective 1, Rho GTPase, homolog 2 (C. elegans) gene (SYDE2)
(Table 1). The SYDE2 protein is by similarity predicted to be a
GTPase activator for Rho-type GTPases (UniProtKB/Swiss-Prot:
Q5VT97). The p.Ala254Thr (rs192842795) variant lies in the
region that has no homology with any other protein, shows poor
sequence conservation among mammals, and was estimated to
be pathogenic only by SIFT, but with low confidence because of
low diversity of sequences in the database. We thus excluded
this variant from further studies.
ZNF528 is by similarity predicted to be a zinc finger protein
implicated in transcriptional regulation (UniProtKB/Swiss-Prot:
Q3MIS6). ZNF528 consists of 3994 bp organized into seven
exons. The c.1282C > T/p.Arg428* (rs150257846) variant is
located in the last exon. A schematic representation of the pre-
dicted effect on protein structure is presented in Fig. 1A. The p.
Arg428* (rs150257846) variant disrupts the 8th C2H2-type zinc
finger of 15 found in the protein and will most likely have an
effect on the function of ZNF528.
ZNF528 has two isoforms. Isoform 1 is 628 amino acids long
and includes one krüppel associated box (KRAB) domain and
15 C2H2-type zinc finger domains. Isoform 2 is missing the first
233 amino acids including the KRAB domain. KRAB domains typ-
ically participate in protein–protein interactions and zinc finger
domains bind specific DNAmotifs.(36) Based on the protein struc-
ture, ZNF528 isoform 1may function as a classical C2H2 type zinc
finger transcription factor. Isoform 1 is expressed in fibroblasts
based on the GTEx database (GTEx Consortium, 2013). The func-
tion of C2H2 zinc fingers lacking the KRAB domain, such as in the
ZNF528 isoform 2, is unknown. Although the variant might affect
both of the isoforms, we focused on ZNF528 isoform 1 because
of its probable function as a DNA-binding transcription factor
and existing data on its expression.
Expression of the ZNF528 and its variant in vitro
Western blot and qPCR were carried out to investigate if a trun-
cated form of ZNF528 with c.1282C > T/p.Arg428* is produced.
mRNA expression was observed in HEK293 cells transfected with
either V5-ZNF528-WT or V5-ZNF528-c.1282C > T, with the
expression of mRNA carrying the variant being lower than the
wild-type mRNA (p = 0.011, Fig. 1B). Western blotting showed
protein products of sizes 73.5 and 47.1 kDa corresponding to
the expected sizes of wild-type ZNF528 and truncated ZNF528,
respectively, confirming that the truncated form is produced
(Fig. 1C, D; Supplemental Figs. S4 and S5).
Subcellular localization of ZNF528 and its variant
Wild-type ZNF528 has previously been shown to localize in the
nucleus and to function as a zinc finger (Zf) transcription factor in
HEK293 cell line.(34) We thus performed immunofluorescence stain-
ing in the human sarcoma osteogenic (Saos-2) cell line and
observed nuclear localization of both the full-length and truncated
V5-tagged ZNF528 proteins (Fig. 2). This was further confirmed in
HEK293 cells by Western blot performed separately from protein
samples of the cytosolic and nuclear fractions (Supplemental
Figs. S6–S8). Overall, these results confirm that the c.1282C > T/p.
Arg428* variant leads to production of the truncated ZNF528 and
that it localizes in the cell nucleus, although a minor amount was
also present in the cytosol. No difference was observed between
ZNF528-WT, ZNF528-c.1282C > T and the control group in cell via-
bility or cytotoxicity assays (Supplemental Figs. S9 and S10).
Expression of ZNF528 in databases
ZNF528 is expressed widely in different human tissues and cell
lines. It has been detected in 53 tissues tested in the GTEx data-
base. mRNA expression is highest in the cerebellum, thyroid,
prostate, and ovary, but it is also present in bone and connective
tissue cell lines (Supplemental Table S3).
Identifying ZNF528 target pathways and genes
Given that both wild-type ZNF528 and its variant localize in the
nucleus, we applied ChIP sequencing to identify their genome-
wide binding sites and to investigate whether they suggest any
potential difference in the target gene regulation. We used
mouse monoclonal V5 antibody to V5-tagged ZNF528-WT and
ZNF528-c.1282C > T, respectively, ectopically expressed in
Saos-2 cells in parallel ChIP sequencing assays. We identified
2279 peaks for ZNF528-WT. In contrast, we revealed more peaks
(29,209) for ZNF528-c.1282C > T (Fig. 3A). Only 19 binding sites
were shared between ZNF528-WT and ZNF528-c.1282C > T
(Fig. 3B), suggesting a distinct global shift in the genomic bind-
ing profile. Examples of ChIP-seq profiles of the differential peak
location for ZNF528-WT and ZNF528-c.1282C > T on two genes
Table 1. Variants Co-segregating With the Phenotype
Gene Rs-number Varianta Function gnomAD Finnish ExAc Finnish SIFT PP-2 MT
ZNF528 rs150257846 c.1282C > T, p.Arg428* Nonsense 0.004 0.006 D NA NA
SYDE2 rs192842795 c.760G > A, p.Ala254Thr Missense 0.002 0.002 Db B P
gnomAD Finnish = the Genome Aggregation Database Finnish data; ExAc Finnish = Exome Aggregation Consortium Finnish data; PP-2 = PolyPhen-2;
MT = Mutation Taster; D = deleterious/damaging; B = benign; P = polymorphism; NA = not available.
aVariant location based on NM_032184 for SYDE and NM_032423 for ZNF528.
bLow confidence.
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are shown in Fig. 3C. Remarkably, de novo motif analysis of ChIP
sequencing peaks showed that ZNF528-WT and
ZNF528-c.1282C > T had distinct binding motifs (Fig. 3D), with
the greatest enrichment for ZNF528 DNA-binding motif in
ZNF528-WT peaks, indicating functionality of the ZNF528 pro-
tein. Moreover, the ZNF528-WT ChIP-seq peaks are also enriched
for three other types of Zf-like motifs (KLF5, ZNF189, and
ZNP467). In contrast, only one type of Zf DNA-binding motif
among top seven was found to be enriched in the ChIP sequenc-
ing peaks of ZNF528-c.1282C > T (ZFP281), suggesting that the
mutation in ZNF528 changes not only its genomewide chroma-
tin binding profile but also DNA-recognition properties.
ZNF528-WT peaks showed association with genes connected
with bone morphology (Fig. 3E; Supplemental Fig. S11A).
Remarkably, we observed highly frequent enrichment of bone-
relevant pathways for ZNF528-c.1282C > T peaks in GREAT cate-
gories of both human and mouse phenotypes (Fig. 3E; Supple-
mental Fig. S11B), presumably due to functional gain of
ZNF528 caused by the mutation. In addition enrichment analysis
of publicly available wild-type ZNF528 ChIP sequencing data(34)
revealed several enriched GO BP, mouse phenotype, and human
phenotype terms in all motif data sets (Supplemental Table S4).
Many of these terms were related to musculoskeletal pheno-
types and related biological processes. Especially those related
to bone morphology were found enriched in the data sets
(Supplemental Table S4), consistent with our ChIP sequencing
data-based analysis shown in Fig. 3E.
To further identify functional target genes of ZNF528-WT or
ZNF528-c.1282C > T and to investigate whether the difference
in their genomic binding profiles is also reflected in gene expres-
sion patterns, we performed RNA sequencing analysis. Com-
pared with a control, we found that 2607 genes were
upregulated, whereas 2507 genes were downregulated by
ectopic ZNF528-WT expression (DESeq2, FDR < 0.01; Fig. 4A),
and 2293 genes were upregulated and 1527 genes were down-
regulated by ectopic ZNF528-c.1282C > T expression (DESeq2,
FDR < 0.01; Fig. 4B). We compared the list of 1695 genes bound
by ZNF528-WT observed by Chip-Seq to the 5114 differentially
expressed genes by ectopic expression of ZNF528-WT and
found that approximately 7% (367 genes) were directly regu-
lated by ZNF528-WT (Fig. 4C). Similar analysis found that
approximately 52% (1995) of expressed genes were directly tar-
geted by ZNF528-c.1282C > T (Fig. 4D). We checked the over-
lapping genes between the 367 ZNF528-WT regulated genes
and 1995 ZNF528-c.1282C > T target genes and found that
187 genes were unique to ZNF528-WT and 1815 to
ZNF528-c.1282C > T (Fig. 4E). Pathway enrichment analysis
showed that ZNF528-c.1282C > T unique target genes
(n = 1815) are significantly enriched in the bone-related path-
ways such as bone morphogenic protein (BMP) signalling and
regulation and endochondral ossification (Fig. 4E). In contrast,
we found no enrichment of ZNF528-WT unique target genes
(n = 187) in the bone-relevant pathways (Supplemental
Fig. S12A).
We next examined whether ZNF528 target genes are likely to
be osteoporosis-related genes by comparing the unique target
genes and the OsteoporosAtlas database. Notably, the results
showed that the fraction of osteoporosis-related genes in the
Fig 1. mRNA and protein expression of V5-ZNF528-WT and V5-ZNF528-c.1282C>T in HEK293 cells. (A) A schematic representation of the predicted effect
of V5-ZNF528-c.1282C>T on ZNF528 protein structure (B) mRNA expression levels determined by qPCR analysis (six replicates) (C) Protein expression
levels determined by western blot. (D) Quantification of western blot results (four technical replicates).
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ZNF528-c.1282C > T unique target gene set is significantly
higher than that of ZNF528-WT unique gene set (Supplemental
Fig. S12B, C; Supplemental Table S5). These include the genes such
as SOX6 and the BMP-SMAD signaling pathway genes BMP2,
BMP6, and SMAD6. Altogether, the pathway and osteoporosis-
related gene enrichment patterns on ZNF528-c.1282C > T are
dramatically different from the ZNF528-WT targeted pathways,
further supporting our findings of their differences in global
genomic binding profiles (Fig. 3B).
For example, in the analysis of the publicly available data
set,(34) the most enriched GO-BP pathways included cartilage
development involved in endochondral bone morphogenesis and
terms relating to cranial morphology. In addition, the terms
abnormal metatarsal and metacarpal bone morphology and
increased vertebrae number were enriched in the mouse pheno-
type database. In the human phenotype, database terms abnor-
mality of the pubic bones and aplasia/hypoplasia of the pubic bone
were enriched. Among these pathways, we identified genes that
had the ZNF528 binding site and had a previously known con-
nection to bone phenotypes (Supplemental Table S6). We con-
sidered these genes as potential ZNF528 target genes for
further analyses.
Expression of ZNF528 and its potential target genes
RNA sequencing
Using RNA sequencing data, we observed that eight genes
were upregulated and three genes downregulated by wild-
type ZNF528 (Fig. 5A) in bone morphology relevant pathways
(Fig. 3E). Furthermore, nine potential bone phenotype-related
ZNF528 target genes were differentially expressed and upre-
gulated by ZNF528-WT (Fig. 5B). We observed that 10 of the
potential ZNF528 target genes presented in Supplemental
Table S6 were differentially regulated by ZNF528-c.1282C > T
compared with ZNF528-WT in our in vitro cell model
(Fig. 5C).
Patient cells
Expression of ZNF528was observed in primary skin fibroblasts. In
patients carrying the c.1282C > T/p.R428X variant, the mRNA
expression of ZNF528 was decreased compared with controls
(Table 2). Eleven of 17 connective tissue-related potential
ZNF528 target genes were differentially expressed in the skin
fibroblasts of two affected family members compared with the
controls. The mRNA expression of seven genes was increased
in patients compared with control: catenin beta 1 (CTNNB1),
CYLD lysine 63 deubiquitinase (CYLD), Dickkopf WNT signaling
pathway inhibitor 1 (DKK1), Estrogen receptor 1 (ESR1), O-
fucosylpeptide 3-beta-N-acetylglucosaminyltransferase (LFNG),
Myocyte Enhancer Factor 2C (MEF2C), and wntless Wnt ligand
secretion mediator (WLS), whereas for five genes it was
decreased: collagen I alpha 2 chain (COL1A2), Jagged 1 (JAG1),
procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 (PLOD2),
and SRY-box 5 (SOX5) (Table 2). No difference was found in the
patients’ fibroblasts in the mRNA expression of the LDL
receptor-related protein 5 (LRP5), TNF superfamily member
Fig 2. Localization of V5-ZNF528-WT and V5-ZNF528-c.1282C > T expression in Saos-2 cells. The locations of ZNF528 (green), nucleus (blue), and actin
(red) were observed through confocal imaging. The nucleus was stained with DAPI and actin filaments with TRITC-Phalloidin. Scale bar = 100 μm.
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Fig 3. Genomewide chromatin binding of ZNF528-WT and ZNF528-c.1282C > T in Saos-2 cells. (A) Pie charts demonstrating genomic distribution fea-
tures of ZNF528-WT or ZNF528-c.1282C > T-binding peaks in Saos-2 cells. The indicated genomic features contain promoters; gene body (50 UTR, 30
UTR, exons, and introns); downstream elements, and distal intergenic regions. UTR = untranslated region. (B) The Venn diagram of overlapping peaks
bound by ZNF528-WT and ZNF528-c.1282C > T in Saos-2 cells. (C) The binding of ZNF528-WT and ZNF528-c.1282C > T on the representative distinct tar-
get genes, RNGTT and GPM6A. The chromosome number and position of the peaks bound by either of the proteins are indicated. (D) The top enriched
motifs in the ZNF528-WT or ZNF528-c.1282C > T-binding peaks determined by HOMER. (E) Functional annotation of ZNF528-c.1282C > T peaks was per-
formed using GREAT. Note that human phenotypes’ ontology category contains data of human genotype–phenotype associations, and the x axis values
(in logarithmic scale) correspond to the binomial raw p values. Bone-related pathways are highlighted in green.
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11 (RANKL), R-spondin 3 (RSPO3), runt-related transcription factor
2 (RUNX2), SRY-box 4 (SOX4), or SRY-box 9 (SOX9), although LRP5
and RUNX2 were downregulated and SOX4 upregulated by
ZNF528-c.1282C > T in our in vitro analysis (Fig. 5C).
Five genes, COL1A2, CTNNB1, DKK1, LFNG, and PLOD2, were
differentially expressed with similar trend (increased or
decreased) in both the patients’ fibroblasts and in the RNA
sequencing experiment (Table 2; Fig. 5C).
Fig 4. Genomewide analysis of ZNF528-WT and ZNF528-c.1282C > T functional target genes. (A, B) Heat maps for the expression level of genes either
down- or upregulated by ZNF528-WT (A) or ZNF528-c.1282C > T (B) overexpression in Saos-2 cells. The indicated number of genes revealed by RNA-
seq (DESeq2, FDR < 0.01). (C, D) Overlap of genes bound (ChIP-seq) or functionally regulated (RNA-seq) by (C) ZNF528-WT or (D) ZNF528-c.1282C > T.
(E) Wikipathways enrichment analysis for ZNF528-c.1282C > T targeted unique genes. The x axis presents logarithmic p value. Bone-related pathways
are highlighted in red.
Journal of Bone and Mineral Researchn 2388 SKARP ET AL.
Discussion
We have identified a rare nonsense variant (c.1282C > T/p.
Arg428*) in ZNF528 in patients who were previously reported
to have a deletion in COL1A2 and suffered from severe early
onset primary osteoporosis but lacked the typical features of
either OI or EDS.(32) The biological function of ZNF528 is poorly
understood and it has not previously been associated with bone
or connective tissue-related phenotypes. The observed variant
results in a truncated ZNF528 protein that locates in the cell
nucleus as per the wild-type protein. We show here that the var-
iant leads to altered DNA binding of ZNF528 and a global shift in
genomic binding profile and pathway enrichment. Furthermore,
the expression of several ZNF528 target genes associated with
bone-related processes is altered in patients’ cells as well as in
in vitro cell model.
ZNF528 belongs to the family of KRAB C2H2 zinc finger pro-
teins, which is the largest family of human transcription fac-
tors.(37) These proteins are typically transcriptional repressors
participating in regulation of embryonic development, apopto-
sis, neoplastic transformation, cell cycle regulation, as well as cell
differentiation and proliferation.(38) They bind to DNA with their
zinc finger domains and the KRAB domain forms a complex with
the KRAB-associated protein 1 (KAP1) to recruit further co-regu-
lators.(36,39) In addition to DNA binding, zinc finger domains also
participate in protein–protein interactions.(40) Thus, the loss of
zinc finger domainsmay also alter the interaction of ZNF528with
other proteins.
ZNF528 is likely to havemultiple biological roles, as supported
by the wide expression pattern observed in the GTEx database.
This was further supported by our results of the enrichment ana-
lyses of ChIP sequencing data sets, where in addition to the
bone-related pathways, terms in other biological processes were
enriched. In general, zinc finger family members tend to be
widely expressed and participate in multiple different biological
pathways.(36,38) For example, ZNF521 and ZNF423 are widely
expressed and in addition to skeletal pathways they have been
described to have a role in mitochondrial fatty acid synthesis,
Fig 5. RNA sequencing analysis showing the genes that are differentially regulated by ZNF528-WT or ZNF528-c.1282C > T. (A) Significant differentially
expressed genes in bone morphology relevant pathways shown in Fig. 5E. (B) Significant differentially expressed genes with ZNF528 binding motifs
shown in Table 2. (C) Significant differentially expressed genes cross-validate patient data shown in Table 2.
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cancer, and Alzheimer’s disease.(41–43) Our data suggest that
ZNF528 could be a regulator of bone-related biological functions
as functional annotation of ZNF528-WT peaks showed enrich-
ment in bone-related mouse phenotype ontology category and
similar results were obtained from analysis of ChIP data from
HEK293 cells.
The variant c.1282C > T/p.Arg428* altered the ZNF528 DNA-
binding motif and led to reprogramming of the global genomic
binding (Fig. 5). This finding was supported by the fact that we
did not observe enrichment of GREAT GO categories among
the ZNF528-c.1282C > T peak-linked genes. As the DNA-
recognition properties of ZNF528 are altered, the target genes
and pathways for ZNF528-WT and ZNF528-c.1282C > T are very
distinct from each other, suggesting that in addition to losing
the original function, there may be an acquisition of novel func-
tions via alterations of the DNA-binding motif.
RNA sequencing showed that wild-type ZNF528 directly regu-
lated 367 genes, many of which belong to cell cycle- and cancer-
related pathways (Fig. 4; Supplemental Fig. S12A). This is not
completely unexpected as the used cell line, Saos-2, is an osteo-
sarcoma cell line. However, our results show that the
c.1282C > T/p.Arg428* variant does alter the underlying biology
and function of ZNF528. More detailed examination of RNA
sequencing results identified several bone morphology-related
genes likely regulated by both wild-type and mutated ZNF528
(Fig. 4; Supplemental Fig. S12A). More osteoporosis-related
genes were affected by ZNF528-c.1282C > T compared with
ZNF528-WT. Thus, the variant may enhance the binding of
ZNF528 in bone-related target genes supporting the role of this
variant in osteoporosis pathogenesis (Supplemental Fig. S12B, C).
To investigate the effect of the c.1282C > T/p.Arg428* variant
on the regulation of bone-associated genes, 17 potential ZNF528
target genes were studied in primary skin fibroblasts obtained
from patients. Eleven of 17 potential ZNF528 target genes were
differentially expressed in patients’ cells compared with controls.
Five of these, including COL1A2, were also differentially
expressed in the RNA sequencing data with similar trend
(increased or decreased expression) when comparing
ZNF528-WT and ZNF528-c.1282C > T. These five genes, COL1A2,
CTNNB1, DKK1, LFNG, and PLOD, are promising targets for
ZNF528 regulation in bone and their expression may be altered
by the c.1282C > T/p.Arg428* variant.
CTNNB1 and DKK1 are part of WNT signaling pathway. Studies
with mice have shown that β-catenin is necessary for controlling
bone development and homeostasis.(44,45) Stabilization of
β-catenin in mature osteoblasts leads to high bone mass pheno-
type, whereas lack of β-catenin leads to osteopenia in mice.(46)
DKK1 is an inhibitor of WNT signaling and variants in DKK1 have
been associated with juvenile osteoporosis.(47) CTNNB1 andDKK1
were upregulated by c.1282C > T/p.Arg428* compared with
ZNF528-WT, suggesting that the variant might contribute to
the patients’ phenotype via this pathway.
LFNGwas similarly upregulated by the c.1282C > T/p.Arg428*
variant. LFNG participates in the Notch signaling pathway by
inhibiting the Notch ligand JAG1,(48) which is required for normal
trabecular bone formation and is the most highly expressed
Notch ligand during skeletal development.(49,50) LFNG is a medi-
ator of somite segmentation and patterning during embryogen-
esis andmodulates Notch signaling by decreasing the binding of
JAG1 to NOTCH2.(51) Mutations in LFNG have also been associ-
ated with spondylocostal dysostosis.(52)
The c.1282C > T/p.Arg428* variant had an opposite effect on
PLOD2, which was downregulated in both patients’ cells and in
the in vitro model. It is a membrane-bound enzyme localized in
endoplasmic reticulum and catalyzes the hydroxylation of lysyl
residues in collagens. Deficiency in lysyl hydroxylase activity is
linked with some cases of kyphoscoliosis type of Ehlers-Danlos
syndrome.(53) Mutations in PLOD2 are associated with Bruck syn-
drome that is characterized by OI and congenital joint
contractures.(54–56)
COL1A2 also harbors the ZNF528 binding site, making it a
potential target gene for ZNF528. We did observe decreased
expression of COL1A2 in patients’ mRNA, but this is consistent
with assumption of nonsense mediated decay caused by the p.
Arg8Phefs*14 deletion.(32) The patients did not carry pathogenic
variants in any of the other potential ZNF528 target genes. It is
not possible to differentiate the putative effect of ZNF528 on
the COL1A2 expression and neither can we exclude the possibil-
ity that the COL1A2 deletion affects the expression of target
genes in the patients’ fibroblasts. However, the COL1A2 expres-
sion and the expression of the five aforementioned potential tar-
get genes were altered by the c.1282C > T/p.Arg428* variant in
the in vitro RNA sequencing experiment. This implies that the
observed ZNF528 variant affects the expression of these genes
independently from the COL1A2 Arg8Phefs*14 deletion. It is
not, however, possible to determine the independent contribu-
tions of the COL1A2 deletion and the ZNF528 variant to the phe-
notype in this family.
In addition to these genes that are likely to contribute to the
patients’ phenotype, our results indicated several other interest-
ing ZNF528 target genes, but for which the effect of c.1282C > T/
p.Arg428* remained unclear (Fig. 5; Table 2). These include
MEF2C and SOX5, which were differentially regulated in both
patient and RNA sequencing data but seemed to have an oppo-
site effect between the data sets. MEF2C is part of the WNT
Table 2. Expression of ZNF528 and Its Potential Target Genes in
Patient Fibroblasts Compared With Controls
Gene p Value Adjusted p value Fold change
ZNF528 0.019 0.0342 0.31#
Potential target genes
COL1A2a 0.006 0.018 0.45#
CTNNB1 1.174 × 10-5 0.0002 3.35"
CYLD 0.007 0.018 3.04"
DKK1 0.025 0.0375 1.67"
ESR1 0.001 0.009 3.95"
JAG1 0.002 0.009 0.57#
LFNG 0.002 0.009 6.19"
LRP5 0.198 0.255 1.2
MEF2C 0.008 0.018 1.73"
PLOD2 0.025 0.0375 0.56#
RANKL 0.048 0.066 0.28
RSPO3 0.267 0.300 2.1
RUNX2 0.626 0.663 0.9
SOX4 0.868 0.868 1.05
SOX5 0.018 0.034 0.27#
SOX9 0.223 0.268 1.67
WLS 0.004 0.014 2.7"
Statistically significant values are bolded. Decreased expression in pri-
mary skin fibroblasts from patients marked with downward pointing
arrow and increased expression with upward pointing arrow. Benjamini
and Hochberg’s false discovery rate correction was applied for the
adjusted p values.
aPatients carry heterozygous p.Arg8Phefs*14 deletion.
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signaling pathway, where it binds to sclerostin (SOST) enhancer
and induces SOST expression, which further inhibits WNT signal-
ing. Lack of SOST leads to high bone mass phenotype.(57) MEF2C
has also been shown to control bone development by activating
chondrocyte hypertrophy.(58) SOX5 encodes a member of Sry-
related transcription factors that regulate chondrocyte differenti-
ation and proliferation.(59) SOX5 has also been associated with
chronic osteochondropathy called Kashin-Beck disease that
affects joints and bones.(60) Our data support the role of
ZNF528 in the regulation of the gene expression of MEF2C and
SOX5, but it is not clear if this has an effect on the patients’ phe-
notype. Transcription factors such as ZNF528 have typically wide
effect on the transcriptome both directly and indirectly. The
function of transcription factors is also often dependent, at least
partially, on cell type or is tissue specific, and pinpointing the
effects of particular variant in specific phenotype is challenging.
Further research is necessary to fully understand the role of
ZNF528 and the observed variant in primary osteoporosis. Over-
all, we provide new information on the function of ZNF528 and
show that it regulates genes and pathways important for bone
development.
In conclusion, we identified a c.1282C > T/p.Arg428* variant
in ZNF528 in a family with severe early onset primary osteoporo-
sis and confirmed that this variant leads to production of trun-
cated ZNF528 in the cell nucleus. The function and targets of
ZNF528 have not been previously reported, but our results indi-
cate that ZNF528 may function as a transcriptional regulator in
several bone-related pathways. We identified five potential tar-
get genes for ZNF528 that were differentially expressed in both
patients’ fibroblasts compared with control cells and in the
in vitro RNA sequencing experiment. The identified ZNF528 vari-
ant may thus contribute to the bone phenotype in the investi-
gated family. These observations suggest that the skeletal
phenotype may even in monogenic disorders such as osteogen-
esis imperfecta be modified by other genes.
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